- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.12. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.11. | AEON Biopharma Inc: AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling | 725 | GlobeNewswire (Europe) | - First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON"... ► Artikel lesen | |
| 14.11. | AEON Biopharma GAAP EPS of -$0.39 | 2 | Seeking Alpha | ||
| 14.11. | AEON Biopharma schedules FDA meeting to review botox biosimilar data | 4 | Investing.com | ||
| 14.11. | AEON Biopharma Inc: AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth | 510 | GlobeNewswire (Europe) | - FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data - - Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing... ► Artikel lesen | |
| 14.11. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| AEON BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.11. | AEON Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.09. | AEON Biopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | AEON Biopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 212 | GlobeNewswire (Europe) | IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 14.05. | AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | 203 | GlobeNewswire (Europe) | - Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
| 25.04. | AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance | 738 | GlobeNewswire (Europe) | IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 21.04. | AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 | 157 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 21.04. | AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer | 762 | GlobeNewswire (Europe) | IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex... ► Artikel lesen | |
| 24.03. | AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 463 | GlobeNewswire (Europe) | - Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 - - Pursuing a 351(k)... ► Artikel lesen | |
| 24.02. | AEON Biopharma, Inc. Announces Reverse Stock Split | 297 | GlobeNewswire (Europe) | IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under... ► Artikel lesen | |
| 07.02. | AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards | 260 | GlobeNewswire (Europe) | IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALTERITY THERAPEUTICS | 0,005 | 0,00 % | XFRA PBN: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOCURE TECHNOLOGY | 0,009 | -62,22 % | Biocure Technology Inc (2): Biocure shareholders approve all matters at AGM | ||
| STRUCTURE THERAPEUTICS | 67,06 | -0,56 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,08 | +0,72 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| COGENT BIOSCIENCES | 42,110 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 40,510 | +2,30 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,83 | +0,32 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| LENZ THERAPEUTICS | 18,140 | -25,96 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,020 | -1,53 % | Amit Munshi joins Arcutis board as founder Chaudhuri retires | ||
| ARCELLX | 71,86 | -1,14 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| MINERALYS THERAPEUTICS | 36,890 | +2,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 41,590 | +1,41 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 33,040 | +4,72 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 89,67 | +2,12 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen |
AEON BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +8,88 % bei einem Aktienkurs von 0,828 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AEON BIOPHARMA INC finden Sie auf Wallstreet Online.